Paper · 42500580
Immunohistochemical Expression of Novel Therapeutic Targets in Squamous Cell Carcinoma of the Bladder.
Frey LJ and 10 others. Oncol Res, 2026. Cited by 0 papers, by iCite.
11 sourcespapers-2026-11-12-0.1.0
Cite this record
ConductScience Library. Immunohistochemical Expression of Novel Therapeutic Targets in Squamous Cell Carcinoma of the Bladder. Papers, record 42500580. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/42500580
On this page
Paper
PubMed's record of the paper, with iCite's citation figures. No abstract is shown.
- Title
- Immunohistochemical Expression of Novel Therapeutic Targets in Squamous Cell Carcinoma of the Bladder.
- PubMed
Topics15
NLM's MeSH indexing of the paper, its major topics first.
| MeSH term | Major |
|---|---|
| Carcinoma, Squamous Cell | Major topic |
| Urinary Bladder Neoplasms | Major topic |
| Biomarkers, Tumor | Major topic |
| Humans | |
| Female | |
| Male | |
| Aged | |
| Middle Aged | |
| Immunohistochemistry | |
| Retrospective Studies | |
| Cell Adhesion Molecules | |
| Nectins | |
| Prognosis | |
| Aged, 80 and over | |
| Adult |
Source PubMed
Grants0
Each grant PubMed's record writes, matched to the NIH project NIH's grant and paper links name for this paper, and each of those links the record does not write.
None in this release.
Trials0
The trials whose ClinicalTrials.gov record lists the paper, and the trial numbers the paper's PubMed record names.
None in this release.
Comments and corrections0
PubMed's comments and corrections, NLM's own indexing: retractions first, then expressions of concern, errata and updates, and comments last.
None in this release.
References32
The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.
| Order | PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|---|
| 1 | 40,097,979 | New insights on anti-tumor immunity of CD8+ T cells: cancer stem cells, tumor immune microenvironment and immunotherapy. | J Transl Med | 2025 | https://conductscience.org/library/papers/40097979 | PubMed |
| 2 | 40,479,863 | Real-world clinical outcomes of sacituzumab govitecan after prior exposure to enfortumab vedotin in patients with metastatic urothelial carcinoma. | ESMO Open | 2025 | https://conductscience.org/library/papers/40479863 | PubMed |
| 3 | 39,764,422 | Targeted therapies and molecular targets in the therapeutic landscape of advanced urothelial carcinoma: state of the art and future perspectives. | Explor Target Antitumor Ther | 2024 | https://conductscience.org/library/papers/39764422 | PubMed |
| 4 | 34,768,219 | Interassay and interobserver comparability study of four programmed death-ligand 1 (PD-L1) immunohistochemistry assays in triple-negative breast cancer. | Breast | 2021 | https://conductscience.org/library/papers/34768219 | PubMed |
| 5 | 34,768,978 | Evaluation of Therapeutic Targets in Histological Subtypes of Bladder Cancer. | Int J Mol Sci | 2021 | https://conductscience.org/library/papers/34768978 | PubMed |
| 6 | 27,841,667 | HER2 Testing and Clinical Decision Making in Gastroesophageal Adenocarcinoma: Guideline From the College of American Pathologists, American Society for Clinical Pathology, and American Society of Clinical Oncology. | Arch Pathol Lab Med | 2016 | https://conductscience.org/library/papers/27841667 | PubMed |
| 7 | 38,873,357 | CEA (CEACAM5) expression is common in muscle-invasive urothelial carcinoma of the bladder but unrelated to the disease course. | BJUI Compass | 2024 | https://conductscience.org/library/papers/38873357 | PubMed |
| 8 | 32,188,412 | Therapeutic implications of PD-L1 expression in bladder cancer with squamous differentiation. | BMC Cancer | 2020 | https://conductscience.org/library/papers/32188412 | PubMed |
| 9 | 30,620,387 | Impact of adjuvant chemotherapy in patients with adverse features and variant histology at radical cystectomy for muscle-invasive carcinoma of the bladder: Does histologic subtype matter? | Cancer | 2019 | https://conductscience.org/library/papers/30620387 | PubMed |
| 10 | 41,152,111 | Efficacy of sacituzumab govitecan after enfortumab vedotin in advanced urothelial carcinoma: Analysis of the UNITE study. | Urol Oncol | 2026 | https://conductscience.org/library/papers/41152111 | PubMed |
1 to 10 of 32
See all 32 referencesCited by0
The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 0 citations.
None in this release.
Genes6
The genes the Gene search release ties to the paper: Swiss-Prot's references first, then PubTator's text mining.
| Gene | NCBI Gene ID | Linked by | In Genes | Source |
|---|---|---|---|---|
| CD274 | 29,126 | PubTator's text mining | https://conductscience.org/library/genes/29126 | NCBI Gene |
| CD8A | 925 | PubTator's text mining | https://conductscience.org/library/genes/925 | NCBI Gene |
| CEACAM5 | 1,048 | PubTator's text mining | https://conductscience.org/library/genes/1048 | NCBI Gene |
| ERBB2 | 2,064 | PubTator's text mining | https://conductscience.org/library/genes/2064 | NCBI Gene |
| NECTIN4 | 81,607 | PubTator's text mining | https://conductscience.org/library/genes/81607 | NCBI Gene |
| TACSTD2 | 4,070 | PubTator's text mining | https://conductscience.org/library/genes/4070 | NCBI Gene |
Drugs0
The drugs whose trials, in the Pipelines release, list the paper.
None in this release.
Data0
The data bank entries PubMed's record names. Trial numbers are under Trials.
None in this release.
Data dates
The date of each source this release read.
- Trials
- 2026-11-12
- Gene search
- 2026-11-11
- Pipelines
- 2026-09-18
Sources 11
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- HGNCCC0
- iCiteCC BY 4.0
- NCBI GenePublic domain (US government)
- NIH RePORTER's grant and paper linksPublic domain
- Open TargetsCC0 1.0
- PMC's ID filePublic domain (US government)
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- HGNCCC0: https://www.genenames.org/about/license/
- iCiteCC BY 4.0
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this paper from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/papers/v1/42500580
GET https://conductscience.org/api/papers/v1/42500580/references?page=2